苏拉明钠盐-CAS 129-46-4-Calbiochem

C₅₁H₃₄N₆O₂₃S₆ · 6Na

1429.17

MFCD00210217

An anti-neoplastic, anti-angiogenic agent that uncouples G-proteins from receptors presumably by blocking their interaction with intracellular receptor domains. A competitive inhibitor of reverse transcriptase. Reported to inhibit topoisomerase I and II. Inhibits Ca²⁺-ATPase in sarcoplasmic reticulum membranes. Also inhibits the cell-surface binding of various growth factors including EGF, PDGF, and TGF-β. An inhibitor of phospholipase D (IC₅₀ = 15 µM). Reported to interact with ATP-binding enzymes and P₂-purinergic receptors. An effective inhibitor of angiogenesis in calmodulin assays when given in combination with angiostatic steroids.
A reversible and competitive inhibitor of protein tyrosine phosphatases. An anti-neoplastic, anti-angiogenic agent that uncouples G-proteins from receptors presumably by blocking their interaction with intracellular receptor domains. Inhibits GDP-GTP exchange, the rate limiting step in the activation of G_α-subunits. A competitive inhibitor of reverse transcriptase. Reported to inhibit topoisomerases I and II. Inhibits Ca²⁺-ATPase in sarcoplasmic reticulum membranes. Also inhibits the cell-surface binding of various growth factors, including EGF, PDGF, and TGF-β. An inhibitor of phospholipase D (IC₅₀ = 15 µM). Reported to interact with ATP-binding enzymes and P₂-purinergic receptors. An effective inhibitor of angiogenesis in the calmodulin assay when given in combination with angiostatic steroids.

Primary Target
protein tyrosine phosphatases
Target IC₅₀: 15 µM against phospholipase D
Product does not compete with ATP.
Cell permeable: no
Reversible: yes

Toxicity: Standard Handling (A)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.

Meyers, M.O., et al. 2000. J. Surg. Res. 91, 130.
Hohenegger, M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 346.
Waldhoer, M., et al. 1998. Mol. Pharmacol. 53, 808.
Zhang, Y.L., et al. 1998. J. Biol. Chem. 273, 12281.
Hohenegger, M., et al. 1996. Mol. Pharmacol. 50, 1443.
Emmick, J.J., et al. 1994. J. Pharmacol. Exp. Ther. 269, 717.
Denhertog, A., et al. 1992. J. Physiol.454, 591.
Nakajima, M., et al. 1991. J. Biol. Chem.266, 9661.
Wilks, J.W., et al. 1991. Int. J. Radiat. Biol.60, 73.
Huang, R.C., et al. 1990. Mol. Pharmacol.37, 304.
Kopp, R. and Pfeiffer, A. 1990. Cancer Res.50, 6490.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

100

≥98% (HPLC)

crystalline solid

Calbiochem^®

OK to freeze
desiccated (hygroscopic)

white

water: 5 mg/mL

ambient

2-8℃

1S/C51H40N6O23S6.6Na/c1-25-9-11-29(49(60)54-37-13-15-41(83(69,70)71)35-21-33(81(63,64)65)23-43(45(35)37)85(75,76)77)19-39(25)56-47(58)27-5-3-7-31(17-27)52-51(62)53-32-8-4-6-28(18-32)48(59)57-40-20-30(12-10-26(40)2)50(61)55-38-14-16-42(84(72,73)74)36-22-34(82(66,67)68)24-44(46(36)38)86(78,79)80;;;;;;/h3-24H,1-2H3,(H,54,60)(H,55,61)(H,56,58)(H,57,59)(H2,52,53,62)(H,63,64,65)(H,66,67,68)(H,69,70,71)(H,72,73,74)(H,75,76,77)(H,78,79,80);;;;;;/q;6*+1/p-6

VAPNKLKDKUDFHK-UHFFFAOYSA-H

50 mg in Plastic ampoule

11 - Combustible Solids

WGK 3